Otros idiomas Evolus, Inc.

Acciones

EOLS

US30052C1071

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
13,3 ^USD	+0,61 %		+16,36 %	+26,31 %

26/04	AbbVie eleva su previsión anual de beneficios por las fuertes ventas de Skyrizi	RE
17/04	Evolus, Inc. Anuncia la publicación de los datos de seguridad y duración del estudio de fase 2 de la formulación "extrafuerte" 40U de Jeuveau	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

AbbVie raises annual profit forecast on strong Skyrizi sales	26/04
Evolus to Report First Quarter Financial Results on May 7, 2024	23/04
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®	17/04
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau	17/04
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	15/04
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	12/04
Evolus, Inc. Announces Board Changes	03/04
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference	26/03
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing	22/03
Evolus Prices $50 Million Share Offering	11/03
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	11/03
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock	11/03
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Sector Update: Health Care Stocks Steady Pre-Bell Friday	08/03
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results, Reaffirms 2024 Guidance	08/03
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours	07/03
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (EOLS) EVOLUS Posts Q4 Revenue $61M, vs. Street Est of $61.1M	07/03
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance	07/03
Evolus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Evolus, Inc.

Acciones

EOLS

US30052C1071

Otros idiomas

Filtros